Common antidepressant may ease long COVID’s crushing fatigue
A randomized trial found that fluvoxamine, a common antidepressant, significantly reduced fatigue and improved quality of life in adults with long COVID. The study involved 399 participants and showed fluvoxamine was more effective than a placebo, offering a potential new treatment for this persistent symptom. Metformin, another medication tested, did not show similar benefits. The findings suggest fluvoxamine could be a viable, low-cost option for managing long COVID fatigue.
A study found that fluvoxamine, a common antidepressant, reduced fatigue in people with long COVID better than a placebo.
This offers a potential, low-cost treatment for a symptom that greatly impacts quality of life for many long COVID patients.
It highlights a practical, evidence-based solution that could help millions and shows how existing drugs can be repurposed for new challenges.
upbeatBytes summarizes in its own words and links to the original publisher — it doesn't host the article.